OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC

September 6th 2024

Moshe Ornstein, MD, MA, discusses the use of first-line IO/TKI doublet regimens in patients with non–clear cell renal cell carcinoma.

Dr Merryman on the Evolution of MRD Assays in Lymphoma

September 5th 2024

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

Dr Kebriaei on the Potential Shift Away From Transplant in ALL

September 5th 2024

Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.

Dr Lee on Treatment Considerations for Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

September 5th 2024

John K. Lee, MD, PhD, discusses treatment considerations for the use of enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.

Dr Koff on the Role of Covalent BTK Inhibitors and Pirtobrutinib in MCL

September 5th 2024

Jean L. Koff, MD, MS, discusses the role of covalent BTK inhibitors in the treatment of mantle cell lymphoma.

Dr Nagpal on the FDA Approval of Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma

September 5th 2024

Seema Nagpal, MD, discusses the FDA approval of vorasidenib for patients with astrocytoma or oligodendroglioma harboring IDH1 or IDH2 mutations.

Dr Cooper on Considerations to Help Guide ADC Use in Second-Line NSCLC

September 5th 2024

Alissa J. Cooper, MD, discusses insights from the TROPION-Lung01 trial that may help guide antibody-drug conjugate use in second-line NSCLC.

Dr Smith on Bispecific Antibodies for the Management of R/R Follicular Lymphoma

September 4th 2024

Sonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.

Dr Giralt on Determining Transplant Eligibility in MDS

September 4th 2024

Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.

Dr Grunwald on the Patient Population and Limitations of the REVEAL Study in PV

September 4th 2024

Michael R. Grunwald, MD, FACP, discusses the characteristics of patients with polycythemia vera enrolled in the REVEAL study and limitations of the study.

Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma

September 4th 2024

Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.

Dr Yekedüz on a Case Study of Adjuvant Treatment Options in ccRCC

September 4th 2024

Emre Yekedüz, MD, discusses a case study shared via social media that evaluated treatment options for a patient with clear cell renal cell carcinoma.

Dr Powell on the FDA Approval of Dostarlimab Plus Chemo in Advanced/Recurrent Endometrial Cancer

September 4th 2024

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Dr Sabari on the FDA Approval of Amivantamab/Lazertinib in EGFR+ Advanced NSCLC

September 4th 2024

Joshua K. Sabari, MD, discusses FDA approval of first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

Dr Arnulf on Managing Tumor Burden for Improved PFS With Ide-Cel in R/R Myeloma

September 4th 2024

Bertrand Arnulf, MD, PhD, discusses the importance of managing tumor burden for improved outcomes with ide-cel in relapsed/refractory multiple myeloma.

Dr Bochner on the Need for Multimodal Approaches in MIBC

September 4th 2024

Bernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.

Dr Tolaney on the Development of TROP2-Directed ADCs in Breast Cancer

September 3rd 2024

Sara M. Tolaney, MD, MPH, discusses the utility of TROP2-directed antibody-drug conjugates in the treatment of patients with breast cancer.

Dr Daver on the Potential Utility of Uproleselan in R/R AML

September 3rd 2024

Naval G. Daver, MD, discusses the potential utility of uproleselan in relapsed/refractory acute myeloid leukemia.

Dr Chase on the FDA Approval of Dostarlimab Plus Chemotherapy in Endometrial Cancer

August 30th 2024

Dana M. Chase, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Dr Tolaney on the Sequential Use of ADCs in Breast Cancer

August 30th 2024

Sara M. Tolaney, MD, MPH, discusses the sequential use of antibody-drug conjugates in the treatment of patients with breast cancer.